Gangqiang Lin, Yi Zhang, Jing Qin, Yong He, Li Fan, Qing Tan, Peng Xie
{"title":"黄腐酚通过Sirt1/NF-κB/NLRP3通路缓解应激诱导的抑郁样行为。","authors":"Gangqiang Lin, Yi Zhang, Jing Qin, Yong He, Li Fan, Qing Tan, Peng Xie","doi":"10.1007/s00213-025-06819-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Depression is a complicated neuropsychiatric disorder with multifactorial etiology, involving alterations in behavior, neuroinflammatory processes, and oxidative homeostasis. Chronic stress disrupts synaptic plasticity and promotes neuroinflammation and redox imbalance, with pronounced effects in the medial prefrontal cortex (mPFC). Xanthohumol (XN), a prenylated flavonoid, has demonstrated neuroprotective properties; however, its therapeutic potential in the context of stress-induced depression has not been fully exploited.</p><p><strong>Objectives: </strong>This study aims to examine whether XN alleviates depressive-like behaviors in a chronic unpredictable mild stress (CUMS) mouse model, as well as to delve into the underlying mechanisms involving neuroinflammation, oxidative stress, synaptic function, and the Sirt1/NF-κB/NLRP3 signaling pathway.</p><p><strong>Methods: </strong>Male C57BL/6J mice were subjected to a 3-week CUMS protocol and administered XN at a dose of 20 mg/kg via intragastric gavage. Behavioral evaluations included the sucrose preference test, tail suspension test, and forced swim test to assess anhedonia and behavioral despair. mPFC tissues were collected for analysis of neuroinflammatory cytokines, Nissl staining, immunofluorescence, oxidative stress biomarkers, and synaptic protein expression. In addition, protein levels of Sirt1, phosphorylated NF-κB (phospho-NF-κB), total NF-κB, and NLRP3 in the mPFC were quantified via western blotting analysis.</p><p><strong>Results: </strong>XN treatment significantly ameliorated depressive-like behaviors and enhanced synaptic protein expression within the mPFC. XN markedly diminished the pro-inflammatory cytokines expression and attenuated oxidative stress via the activation of the Nrf2/HO-1 signaling pathway, thereby boosting the brain's antioxidant capacity. Additionally, XN upregulated the expression of Sirt1 and suppressed the NF-κB/NLRP3 inflammasome pathway activation.</p><p><strong>Conclusions: </strong>XN exerts antidepressant-like impact through the Sirt1/NF-κB/NLRP3 and Nrf2/HO-1 pathways, highlighting XN as a potentially effective therapeutic alternative for stress-induced depression.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Xanthouhumol relieves stress-induced depressive-like behaviors through the Sirt1/NF-κB/NLRP3 pathway.\",\"authors\":\"Gangqiang Lin, Yi Zhang, Jing Qin, Yong He, Li Fan, Qing Tan, Peng Xie\",\"doi\":\"10.1007/s00213-025-06819-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>Depression is a complicated neuropsychiatric disorder with multifactorial etiology, involving alterations in behavior, neuroinflammatory processes, and oxidative homeostasis. Chronic stress disrupts synaptic plasticity and promotes neuroinflammation and redox imbalance, with pronounced effects in the medial prefrontal cortex (mPFC). Xanthohumol (XN), a prenylated flavonoid, has demonstrated neuroprotective properties; however, its therapeutic potential in the context of stress-induced depression has not been fully exploited.</p><p><strong>Objectives: </strong>This study aims to examine whether XN alleviates depressive-like behaviors in a chronic unpredictable mild stress (CUMS) mouse model, as well as to delve into the underlying mechanisms involving neuroinflammation, oxidative stress, synaptic function, and the Sirt1/NF-κB/NLRP3 signaling pathway.</p><p><strong>Methods: </strong>Male C57BL/6J mice were subjected to a 3-week CUMS protocol and administered XN at a dose of 20 mg/kg via intragastric gavage. Behavioral evaluations included the sucrose preference test, tail suspension test, and forced swim test to assess anhedonia and behavioral despair. mPFC tissues were collected for analysis of neuroinflammatory cytokines, Nissl staining, immunofluorescence, oxidative stress biomarkers, and synaptic protein expression. In addition, protein levels of Sirt1, phosphorylated NF-κB (phospho-NF-κB), total NF-κB, and NLRP3 in the mPFC were quantified via western blotting analysis.</p><p><strong>Results: </strong>XN treatment significantly ameliorated depressive-like behaviors and enhanced synaptic protein expression within the mPFC. XN markedly diminished the pro-inflammatory cytokines expression and attenuated oxidative stress via the activation of the Nrf2/HO-1 signaling pathway, thereby boosting the brain's antioxidant capacity. Additionally, XN upregulated the expression of Sirt1 and suppressed the NF-κB/NLRP3 inflammasome pathway activation.</p><p><strong>Conclusions: </strong>XN exerts antidepressant-like impact through the Sirt1/NF-κB/NLRP3 and Nrf2/HO-1 pathways, highlighting XN as a potentially effective therapeutic alternative for stress-induced depression.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06819-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06819-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Xanthouhumol relieves stress-induced depressive-like behaviors through the Sirt1/NF-κB/NLRP3 pathway.
Rationale: Depression is a complicated neuropsychiatric disorder with multifactorial etiology, involving alterations in behavior, neuroinflammatory processes, and oxidative homeostasis. Chronic stress disrupts synaptic plasticity and promotes neuroinflammation and redox imbalance, with pronounced effects in the medial prefrontal cortex (mPFC). Xanthohumol (XN), a prenylated flavonoid, has demonstrated neuroprotective properties; however, its therapeutic potential in the context of stress-induced depression has not been fully exploited.
Objectives: This study aims to examine whether XN alleviates depressive-like behaviors in a chronic unpredictable mild stress (CUMS) mouse model, as well as to delve into the underlying mechanisms involving neuroinflammation, oxidative stress, synaptic function, and the Sirt1/NF-κB/NLRP3 signaling pathway.
Methods: Male C57BL/6J mice were subjected to a 3-week CUMS protocol and administered XN at a dose of 20 mg/kg via intragastric gavage. Behavioral evaluations included the sucrose preference test, tail suspension test, and forced swim test to assess anhedonia and behavioral despair. mPFC tissues were collected for analysis of neuroinflammatory cytokines, Nissl staining, immunofluorescence, oxidative stress biomarkers, and synaptic protein expression. In addition, protein levels of Sirt1, phosphorylated NF-κB (phospho-NF-κB), total NF-κB, and NLRP3 in the mPFC were quantified via western blotting analysis.
Results: XN treatment significantly ameliorated depressive-like behaviors and enhanced synaptic protein expression within the mPFC. XN markedly diminished the pro-inflammatory cytokines expression and attenuated oxidative stress via the activation of the Nrf2/HO-1 signaling pathway, thereby boosting the brain's antioxidant capacity. Additionally, XN upregulated the expression of Sirt1 and suppressed the NF-κB/NLRP3 inflammasome pathway activation.
Conclusions: XN exerts antidepressant-like impact through the Sirt1/NF-κB/NLRP3 and Nrf2/HO-1 pathways, highlighting XN as a potentially effective therapeutic alternative for stress-induced depression.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.